Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.
The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate was used to treat 15 patients with recurrent and metastatic endometrial cancer. Four patients had a complete response and one patient had a partial response, yielding a total response rate of 33%. Five patients had stable disease. The median survival for the whole group was 38 weeks. The median survival for responders was 60 weeks, and that for nonresponders was 21 weeks. The median progression-free survival for the whole group was 17 weeks. The median progression-free survival for responders was 32 weeks, and that for patients with stable disease was 25 weeks. The toxic reactions noted were primarily nausea, vomiting, and myelosuppression. The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate has modest effectiveness in the treatment of metastatic or recurrent carcinoma of the endometrium.
Hoffman
M S
MS
H. Lee Moffitt Cancer Center & Research Institute Division of Gynecologic Oncology, University of South Florida College of Medicine, Tampa 33682-0179.
Roberts
W S
WS
Cavanagh
D
D
Praphat
H
H
Solomon
P
P
Lyman
G H
GH
D015250:Aclarubicin / Q000008:administration & dosage; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008535:Megestrol / Q000008:administration & dosage / Q000031:analogs & derivatives; D019290:Megestrol Acetate; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017663:Peplomycin; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality
D001761:Bleomycin; D017663:Peplomycin; D015250:Aclarubicin; D008535:Megestrol; D002945:Cisplatin; D019290:Megestrol Acetate